Literature DB >> 10420531

[Rectal carcinoma. Optimizing therapy by local excision].

A Heintz1, M Mörschel, T Junginger.   

Abstract

The results of local excision and radical surgery in patients with T1-carcinomas of the rectum were compared. In a retrospective study (1.1.1985-1.7.1997) the results obtained in 107 patients with T1-rectal carcinoma ("low risk" T1: n = 83, "high risk" T1: n = 24) undergoing local excision or radical surgical therapy were compared. The complication rate in patients undergoing local excision was 3.3% (2/60) and ranged at 19% (9/47) in the group treated with radical surgery. Two out of 47 patients (4.2%) died after radical resection; there were no deaths after local excision. With regard to the actuarial 5-year survival rate, in the group with "low risk" T1 carcinoma no difference was observed between patients treated with local excision (79%) or radical resection (81%) (p = 0.72). In patients with "high risk" T1 carcinoma lymph node metastases were identified in 4 out of 11 patients undergoing radical resection (36%). 4 out of 13 patients with "high risk" T1 carcinoma treated by local excision developed recurrences, while none of the patients undergoing primary radical surgery had a recurrence. This underlines the necessity of radical surgery in "high risk" T1-carcinomas. Local excision for the treatment of "low risk" T1-carcinoma is associated with a significantly lower complication rate than the performance of a radical surgical therapy. There is no difference in five-year-survival between local and radical surgical therapy in patients with "low risk" T1 carcinoma.

Entities:  

Mesh:

Year:  1999        PMID: 10420531

Source DB:  PubMed          Journal:  Zentralbl Chir        ISSN: 0044-409X            Impact factor:   0.942


  1 in total

1.  [Selection of patients with rectal tumors for local excision based on preoperative diagnosis. Results of a consecutive evaluation study of 552 patients].

Authors:  W Kneist; A Terzic; J Burghardt; A Heintz; T Junginger
Journal:  Chirurg       Date:  2004-02       Impact factor: 0.955

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.